Evaluation of a Novel Point-of-Care Diagnostic Test for Human Papillomavirus (HPV)
ConditionHuman Papillomavirus
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexFemale
Age21+
SponsorM.D. Anderson Cancer Center
About this trial
To learn if new HPV tests can provide the same results as standard HPV tests. The findings from this study may aid in the development of new HPV tests that require less equipment and are more accessible.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
People with a cervix 21 years of age or older.
Scheduled to undergo hrHPV testing at MD Anderson and The Harris Health System (LBJ Hospital) according to national and institutional guidelines at time of enrollment OR are anticipated to undergo a LEEP, ECC, or biopsy.
Willing and able to provide informed consent.
Able to perform protocol-required activities. Able to speak and read English or Spanish.
Disqualifiers
Patient or provider decision not to perform HPV testing. This does not apply to patients that are undergoing either a LEEP, ECC or biopsy.
Participant or provider decision not to collect a sample for this study.
Participants that are pregnant.
Trial population
MD Anderson Cancer Center
Trial design
Design model
Case-only
Time perspective
Cross-sectional
Treatments tested in this trial
Novel point-of-care diagnostic test for detecting HPV ("Rice HPV test")
Diagnostic testGiven by Diagnostic Test
Treatment groups
600 Participants
are divided into 1 treatment groupGroup A: Research Group1 intervention
Trial outcomes
Primary outcomes
1
Novel point-of-care diagnostic test for detecting HPV ("Rice HPV test")
To evaluate the performance of the 3 version of a novel point-of-care diagnostic test for detecting HPV ("Rice HPV test").
Time frame
Through study completion; an average of 1 yearSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov